Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19823
Full metadata record
DC FieldValueLanguage
dc.contributor.authorForsyth, Cecily J-
dc.contributor.authorChan, Wai-Hoong-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorCook, Nathalie C-
dc.contributor.authorLane, Steven W-
dc.contributor.authorBurbury, Kate L-
dc.contributor.authorPerkins, Andrew C-
dc.contributor.authorRoss, David M-
dc.date2018-11-08-
dc.date.accessioned2018-11-26T00:51:08Z-
dc.date.available2018-11-26T00:51:08Z-
dc.date.issued2019-
dc.identifier.citationInternal Medicine Journal 2019; 49(8): 948-954-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/19823-
dc.description.abstractThe classical myeloproliferative neoplasms (MPN) are uncommon clonal haematopoietic malignancies characterised by excessive production of mature blood cells. Clinically they are associated with thrombosis, haemorrhage, varying degrees of constitutional disturbance, and a risk of progression to myelofibrosis or acute myeloid leukaemia. Many of the disease manifestations may be ameliorated by treatment with interferon-α (IFN) but its use in Australian MPN patients has been limited due to the inconvenience of frequent injections and side effects. The pegylated form of IFN is a long-acting preparation which is better tolerated and its Pharmaceutical Benefits Scheme listing is likely to lead to increased usage. We review the literature on risks and benefits of IFN treatment for MPNs, suggest criteria for patient selection in each of these diseases, and discuss strategies to manage the side effects of pegylated IFN. This article is protected by copyright. All rights reserved.-
dc.language.isoeng-
dc.titleRecommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.-
dc.typeJournal Article-
dc.identifier.journaltitleInternal Medicine Journal-
dc.identifier.affiliationDepartment of Medicine, Wyong Hospital Wyong, NSW-
dc.identifier.affiliationDepartment of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Nutrition and Dietetics, Banyule Community Health, Melbourne, VICen
dc.identifier.affiliationMPN Alliance, Australiaen
dc.identifier.affiliationDepartment of Haematology, Royal Brisbane and Women's Hospital, and Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, QLDen
dc.identifier.affiliationSchool of Medicine, University of Queensland, Brisbane, QLDen
dc.identifier.affiliationDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC-
dc.identifier.affiliationDepartment of Clinical Haematology, The Alfred Hospital, Melbourne, VIC-
dc.identifier.affiliationDepartment of Haematology, Royal Adelaide Hospital and Flinders Medical Centre, and Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA-
dc.identifier.doi10.1111/imj.14154-
dc.identifier.orcid0000-0002-9108-3088-
dc.identifier.orcid0000-0002-4674-3403-
dc.identifier.pubmedid30411442-
dc.type.austinJournal Article-
dc.type.austinReview-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Jan 27, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.